Hikma's generic Advair faces U.S. delay, 2017 approval unlikely

LONDON (Reuters) - Hikma Pharmaceuticals said on Thursday that U.S. regulators had decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair at this time, due to 'major' issues with its application.